These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23015323)

  • 1. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Rahimi Jamnani F; Aghaee Bakhtiari SH
    Mol Biotechnol; 2013 Jun; 54(2):590-601. PubMed ID: 23015323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Sharifzadeh Z
    Exp Cell Res; 2012 Jun; 318(10):1112-24. PubMed ID: 22440788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
    Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of camel nanobodies specific for superfolder GFP fusion proteins.
    Twair A; Al-Okla S; Zarkawi M; Abbady AQ
    Mol Biol Rep; 2014 Oct; 41(10):6887-98. PubMed ID: 25085037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
    Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
    J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.
    Irvine K; Schlom J
    Cancer Immunol Immunother; 1993 May; 36(5):281-92. PubMed ID: 7682893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.
    Nicolet CM; Siegel DH; Surfus JE; Sondel PM
    Tumour Biol; 1997; 18(6):356-66. PubMed ID: 9372869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
    Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
    Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new breast cancer-associated antigen and its relationship to MUC1 and TAG-72 antigens.
    Harada Y; Ohuchi N; Masuko T; Funaki Y; Mori S; Satomi S; Hashimoto Y
    Tohoku J Exp Med; 1996 Nov; 180(3):273-88. PubMed ID: 9058511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies.
    Kuroki M; Fernsten PD; Wunderlich D; Colcher D; Simpson JF; Poole DJ; Schlom J
    Cancer Res; 1990 Aug; 50(16):4872-9. PubMed ID: 1696162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenobody and RANbody-based sandwich enzyme-linked immunosorbent assay to detect Newcastle disease virus.
    Ji P; Zhu J; Li X; Fan W; Liu Q; Wang K; Zhao J; Sun Y; Liu B; Zhou EM; Zhao Q
    J Nanobiotechnology; 2020 Mar; 18(1):44. PubMed ID: 32169061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.
    Merikhian P; Darvishi B; Jalili N; Esmailinejad MR; Khatibi AS; Kalbolandi SM; Salehi M; Mosayebzadeh M; Barough MS; Majidzadeh-A K; Yadegari F; Rahbarizadeh F; Farahmand L
    Mol Oncol; 2022 Jan; 16(2):485-507. PubMed ID: 34694686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.
    Dhaouadi S; Ben Abderrazek R; Loustau T; Abou-Faycal C; Ksouri A; Erne W; Murdamoothoo D; Mörgelin M; Kungl A; Jung A; Ledrappier S; Benlasfar Z; Bichet S; Chiquet-Ehrismann R; Hendaoui I; Orend G; Bouhaouala-Zahar B
    Front Immunol; 2021; 12():635166. PubMed ID: 33790905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris.
    Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh AA
    Mol Immunol; 2006 Feb; 43(5):426-35. PubMed ID: 16337485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin.
    Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh A; Sarrami R; Nasiry H; Sadeghizadeh M
    Immunol Invest; 2005; 34(4):431-52. PubMed ID: 16302687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
    Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
    Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.
    Kazemi-Lomedasht F; Behdani M; Rahimpour A; Habibi-Anbouhi M; Poshang-Bagheri K; Shahbazzadeh D
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):201-5. PubMed ID: 26090598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.